Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance.

ABSTRACT:

Importance

The federal Hospital Price Transparency final rule, which became effective in 2021, requires hospitals to publicly disclose payer-specific prices for drugs. However, little is known about hospital markup prices for parenterally administered therapies.

Objective

To assess the extent of price markup by hospitals on parenterally administered cancer therapies and price variation among hospitals and between payers at each hospital.

Design, setting, and participants

A cross-sectional analysis was conducted of private payer-specific negotiated prices for the top 25 parenteral (eg, injectable or infusible) cancer therapies by Medicare Part B spending in 2019 using publicly available hospital price transparency files. Sixty-one National Cancer Institute (NCI)-design

SUBMITTER: Xiao R 

PROVIDER: S-EPMC9016607 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature